Savara (NASDAQ:SVRA) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Savara (NASDAQ:SVRA) announced its quarterly earnings data on Thursday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02), Zacks reports. The company had revenue of $0.27 million for the quarter.

Savara Price Performance

Shares of NASDAQ:SVRA opened at $2.76 on Friday. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. The company has a 50 day moving average of $2.72 and a 200 day moving average of $3.27. The stock has a market cap of $473.84 million, a P/E ratio of -6.47 and a beta of 0.60. Savara has a 12 month low of $2.26 and a 12 month high of $5.34.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. JMP Securities reissued a “market outperform” rating and issued a $9.00 target price on shares of Savara in a report on Thursday, December 19th. Wells Fargo & Company initiated coverage on shares of Savara in a research note on Friday, December 20th. They issued an “overweight” rating and a $8.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Savara in a research note on Friday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.83.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.